{"id":"mesalazine-asacol-800-mg","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Headache"},{"rate":"5-10","effect":"Abdominal pain"},{"rate":"5-10","effect":"Diarrhea"},{"rate":"3-8","effect":"Nausea"},{"rate":"1-3","effect":"Rash"},{"rate":"<1","effect":"Nephrotoxicity (rare)"}]},"_chembl":{"chemblId":"CHEMBL3700835","moleculeType":"Small molecule","molecularWeight":"365.41"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Mesalazine (5-aminosalicylic acid) is a topical anti-inflammatory agent that acts locally in the colon to suppress inflammatory mediators and reduce immune cell activation. It inhibits nuclear factor-kappa B (NF-κB) signaling and decreases production of pro-inflammatory cytokines, thereby reducing mucosal inflammation in inflammatory bowel disease.","oneSentence":"Mesalazine reduces intestinal inflammation by inhibiting prostaglandin and leukotriene production in the colon.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:41:20.801Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ulcerative colitis, mild to moderate"},{"name":"Crohn's disease, mild to moderate"},{"name":"Maintenance of remission in inflammatory bowel disease"}]},"trialDetails":[{"nctId":"NCT04133194","phase":"PHASE4","title":"Adherence of a 1.600 mg Single Tablet 5-ASA Treatment of Ulcerative Colitis","status":"UNKNOWN","sponsor":"Flemming Bendtsen","startDate":"2019-11-28","conditions":"Ulcerative Colitis","enrollment":200},{"nctId":"NCT01469637","phase":"PHASE1","title":"Sulfamethoxazole Drug Interaction Study With MMX® Mesalazine/Mesalamine","status":"COMPLETED","sponsor":"Shire","startDate":"2011-11-07","conditions":"Healthy","enrollment":44},{"nctId":"NCT00151892","phase":"PHASE3","title":"Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis","status":"COMPLETED","sponsor":"Shire","startDate":"2005-04-08","conditions":"Ulcerative Colitis","enrollment":829},{"nctId":"NCT00708656","phase":"PHASE3","title":"The Colitis Once Daily Asacol Study","status":"COMPLETED","sponsor":"Cardiff and Vale University Health Board","startDate":"2006-10","conditions":"Ulcerative Colitis","enrollment":213},{"nctId":"NCT01696942","phase":"PHASE4","title":"Cimzia Versus Mesalamine for Crohn's Recurrence","status":"TERMINATED","sponsor":"Milton S. Hershey Medical Center","startDate":"2013-02","conditions":"Crohn's Disease","enrollment":10},{"nctId":"NCT01059344","phase":"PHASE3","title":"Efficacy and Safety of Asacol™ 4.8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Tillotts Pharma AG","startDate":"2009-11","conditions":"Ulcerative Colitis","enrollment":281},{"nctId":"NCT02077777","phase":"PHASE2","title":"Chemopreventive Action of Mesalazine on Colorectal Cancer: a Pilot Study for an \"in Vivo\" Evaluation of the Molecular Effects on β-catenin Signaling Pathway.","status":"COMPLETED","sponsor":"SOFAR S.p.A.","startDate":"2012-10","conditions":"Colorectal Cancer","enrollment":21},{"nctId":"NCT02190526","phase":"PHASE4","title":"Effects of Mesalamine and Amitriptyline on Irritable Bowel Syndrome","status":"WITHDRAWN","sponsor":"Tehran University of Medical Sciences","startDate":"2014-09","conditions":"Diarrhea- Predominant Irritable Bowel Syndrome, Quality of Life","enrollment":""},{"nctId":"NCT00073021","phase":"PHASE3","title":"Safety and Efficacy of Two Different Doses of Asacol in the Treatment of Moderately Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2000-09","conditions":"Ulcerative Colitis","enrollment":386},{"nctId":"NCT00626288","phase":"PHASE3","title":"Mesalazine Therapy in Patients With Irritable Bowel Syndrome","status":"COMPLETED","sponsor":"SOFAR S.p.A.","startDate":"2007-12","conditions":"Irritable Bowel Syndrome","enrollment":187},{"nctId":"NCT00350415","phase":"PHASE3","title":"A Double Blind Study for the Treatment of Acute Ulcerative Colitis","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2006-06","conditions":"Ulcerative Colitis","enrollment":772},{"nctId":"NCT01534754","phase":"PHASE4","title":"Mesalazine and/or Lactobacillus Casei in the Diverticular Disease of the Colon","status":"COMPLETED","sponsor":"Hospital Cristo Re","startDate":"2009-01","conditions":"Diverticular Disease of the Colon","enrollment":250},{"nctId":"NCT00577473","phase":"PHASE3","title":"Safety and Efficacy of Asacol 4.8 g/Day Versus Asacol 2.4 g/Day (ASCEND I)","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2001-02","conditions":"Ulcerative Colitis","enrollment":301},{"nctId":"NCT00774007","phase":"PHASE2, PHASE3","title":"A Randomized Controlled Pilot Trial of Mesalazine in Patients With Irritable Bowel Syndrome","status":"COMPLETED","sponsor":"SOFAR S.p.A.","startDate":"2004-09","conditions":"Irritable Bowel Syndrome","enrollment":20},{"nctId":"NCT00092508","phase":"PHASE3","title":"CORE: A Study of OPC-6535 With Asacol® in Maintaining Ulcerative Colitis (UC) Remission","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2004-05","conditions":"Ulcerative Colitis","enrollment":1725}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Mesalazine(asacol 800 mg)","genericName":"Mesalazine(asacol 800 mg)","companyName":"Tehran University of Medical Sciences","companyId":"tehran-university-of-medical-sciences","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mesalazine reduces intestinal inflammation by inhibiting prostaglandin and leukotriene production in the colon. Used for Ulcerative colitis (induction and maintenance of remission), Crohn's disease (colonic involvement).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}